Prostate Cancer Clinical Trials in Ohio

Showing 141-160 of 397 trials

LTFU for All Cell and Gene Therapy Studies

NCT06194461

Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.

Hepatocellular CarcinomaProstate Cancer

AstraZeneca64 participantsStarted Sep 2025

Phoenix, Arizona, United States • Duarte, California, United States • Orange, California, United States +22 more locations

COMPLETEDPhase 332 miles

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

NCT04100018

The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.

Prostate Cancer

Bristol-Myers Squibb1,030 participantsStarted Feb 2020

Mobile, Alabama, United States • Anchorage, Alaska, United States • Tucson, Arizona, United States +290 more locations

LTFU for All Cell and Gene Therapy Studies

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Prostate Cancer Trials in Other Cities

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Clinical Trial of Approaches to Prostate Cancer Surgery

Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Other Conditions in Ohio